These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34888514)

  • 21. Development of bullous pemphigoid during the haemodialysis of a young man: case report and literature survey.
    Osipowicz K; Kalinska-Bienias A; Kowalewski C; Wozniak K
    Int Wound J; 2017 Feb; 14(1):288-292. PubMed ID: 27748034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
    Rasmussen LH; Larsen TB; Graungaard T; Skjøth F; Lip GY
    BMJ; 2012 Nov; 345():e7097. PubMed ID: 23129490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bullous pemphigoid-like skin rash associated with Rivaroxaban use in a very elderly patient with multimorbidity and chronic kidney disease: A case report.
    Chohan SA; Balasubramanian D; Ee S
    Clin Case Rep; 2020 Apr; 8(4):725-730. PubMed ID: 32274046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global Prospective Safety Analysis of Rivaroxaban.
    Kirchhof P; Radaideh G; Kim YH; Lanas F; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ;
    J Am Coll Cardiol; 2018 Jul; 72(2):141-153. PubMed ID: 29976287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Proietti M; Romanazzi I; Romiti GF; Farcomeni A; Lip GYH
    Stroke; 2018 Jan; 49(1):98-106. PubMed ID: 29167388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
    Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
    J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation.
    Jansson M; Själander S; Sjögren V; Renlund H; Norrving B; Själander A
    Thromb Res; 2020 Jan; 185():135-141. PubMed ID: 31816553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
    Collings SL; Vannier-Moreau V; Johnson ME; Stynes G; Lefèvre C; Maguire A; Asmar J; Bizouard G; Duhot D; Mouquet F; Fauchier L
    Arch Cardiovasc Dis; 2018 May; 111(5):370-379. PubMed ID: 29398546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
    Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
    Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
    Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N
    Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.